Buparlisib is a pan-PI3K inhibitor that has been evaluated in the BELLE-2 study as monotherapy or has been used in combination with ET and/or anti-HER2 therapy or cytotoxics in PIK3CA-mutant breast cancer cases (17). This evidence concerns the gene ERBB2 and breast cancer.